广泛期小细胞肺癌预防性颅脑照射的采用:一项基于人群的结局研究
该研究在新加坡两家国家癌症中心纳入2003至2010年诊断的无脑转移广泛期小细胞肺癌患者,比较2007年欧洲随机对照试验发表前后预防性颅脑照射的使用变化,并分析其与生存的关系。结果显示,一线化疗后至少疾病稳定的患者中预防性颅脑照射使用率从10%升至32%(P=0.044),多变量分析中预防性颅脑照射与总生存改善相关(HR 0.22,95%CI 0.10至0.47,P<0.001)。
要点
- 一线化疗后至少疾病稳定的患者中,预防性颅脑照射使用率从2003至2006年的10%升至2007至2010年的32%(P=0.044)。
- 多变量分析中,预防性颅脑照射与总生存改善相关(HR 0.22,95%CI 0.10至0.47,P<0.001)。
- 作者认为欧洲随机对照试验结果在真实世界实践中可重现。
核心结论
- 自2007年以来,广泛期小细胞肺癌预防性颅脑照射的采用有所增加。
- 在预防性颅脑照射前未强制进行脑MRI检查且一线化疗后疾病稳定或更好的患者中,预防性颅脑照射与生存改善相关,提示欧洲随机对照试验结果在真实世界实践中可重现。
研究设计与样本
- 研究在新加坡仅有的两家国家癌症中心识别2003至2010年诊断的 eligible 患者,并将电子病历与国家死亡登记链接。
- 比较2003至2006年诊断患者(采用前队列)与2007至2010年诊断患者(采用后队列)中预防性颅脑照射的使用情况。
- 采用单变量和多变量Cox回归分析评估预防性颅脑照射与生存的关联。
主要发现
- 共识别224例无脑转移的广泛期小细胞肺癌患者。
- 在71例一线化疗后至少疾病稳定的患者中,预防性颅脑照射使用率从2003至2006年的10%升至2007至2010年的32%(P=0.044)。
- 多变量分析中,与未接受预防性颅脑照射相比,预防性颅脑照射与总生存改善相关(HR 0.22,95%CI 0.10至0.47,P<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The survival benefit of PCI in ES-SCLC reported by a European randomized trial (RCT) in 2007 was not replicated by a Japanese RCT published in 2017. This study aimed to evaluate the uptake of PCI before and after publication of the European RCT and its association with survival in ES-SCLC. METHODS: We identified eligible patients in the only two Singapore national cancer centres from 2003 to 2010. We linked their electronic medical records to the national death registry. We described the utilization of PCI in patients diagnosed from 2003 to 2006 (pre-adoption cohort) with patients diagnosed from 2007 to 2010 (post-adoption cohort). We performed univariable and multivariable Cox regression analysis to assess the association between PCI and survival. RESULTS: We identified 224 patients with ES-SCLC with no brain metastases. Among the 71 patients who had at least stable disease after first line chemotherapy, there was an increase in the use of PCI from the period 2007 to 2010 compared with 2003 to 2006 (32% versus 10%, P = 0.044). PCI was associated with improved OS (hazard ratio 0.22, 95% CI 0.10 to 0.47, P < 0.001) compared to no PCI in the multivariable analysis. CONCLUSION: There was an increase in the adoption of PCI for ES-SCLC since 2007. PCI was associated with improved survival in patients who did not have mandatory MRI brain imaging prior to PCI and had stable disease or better after first line chemotherapy, suggesting that the results of the European RCT are reproducible in the real-world practice.
引用
- Soon YY, Zheng H, Ho SZ, et al. Adoption of prophylactic cranial irradiation (PCI) for extensive stage small cell lung cancer (ES-SCLC): a population based outcome study. Radiat Oncol. 2018. PMID: 30547818. doi:10.1186/s13014-018-1184-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。